Australia Docosahexaenoic acid DHA market Size & Outlook, 2026-2034
Australia Docosahexaenoic acid DHA market Insights
- As per Reed Intelligence insights, the Australia Docosahexaenoic acid DHA market stood at USD 36.52 Million in 2025 and is anticipated to grow to USD 73.71 Million by 2034.
- The Australia market is expected to advance at a CAGR of 7.95% from 2026 through 2034.
- In 2025, Fish Oil accounted for the highest share of the By Source market size.
- During the forecast period, Fish Oil is set to register the highest growth, making it the most lucrative By Source segment.
![Australia Docosahexaenoic acid DHA market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/australia-docosahexaenoic-acid-dha-market-australia-by-source-212477.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Australia accounted for 0.98% of the global Docosahexaenoic acid DHA market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within Asia Pacific, China is forecasted to dominate the regional Docosahexaenoic acid DHA market size by 2034.
- Taiwan will be the fastest-growing market in Asia Pacific, projected to achieve USD 74.6 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 36.52 Million |
| Market Size In 2034 | USD 73.71 Million |
| Largest segment | Fish Oil |
| Units | Revenue in USD Million |
| CAGR | 7.95% (2026-2034) |
| Segmnetation Covered | |
| By Source |
|
| By Form |
|
| By Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Australia Docosahexaenoic acid DHA market By Source 2026-2034 (USD Million)
| By Source | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fish Oil | XX.x | XX.x | XX.x | 14.63 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Algae Oil | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Krill Oil | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia Docosahexaenoic acid DHA market By Form 2026-2034 (USD Million)
| By Form | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oil | XX.x | XX.x | XX.x | 18.67 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Powder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Capsules and Softgels | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia Docosahexaenoic acid DHA market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infant Formula | XX.x | XX.x | XX.x | 14.05 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dietary Supplements | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Functional Food and Beverages | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceuticals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Animal Feed | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.